ClinicalTrials.gg
RecruitingNCT05998694TiAraUpdated Sep 25, 2024

Post-market Clinical Monitoring of the Safety and Efficacy of the Aortic Valve Bioprothesis

An observational study in Aortic Valve Disease and Artificial Heart Valves, sponsored by Closed Joint-Stock Company NeoCor. Recruiting at 1 site in Russian Federation. Open to participants aged 60 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Closed Joint-Stock Company NeoCor · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,000
Ages
60 Years to 70 Years
Sex
All
01

Study summary

The goal of this multicenter prospective cohort study is to evaluate the long-term safety and efficacy of clinical outcomes of aortic valve replacement using the "TiAra" prosthesis with or without concomitant procedures.

Main research objectives:

  1. To analyze the short and mid-term (up to 3 years) outcome of aortic valve replacement using the "TiAra" prosthesis.
  2. To study the hemodynamic characteristics of normally functioning "TiAra" prostheses in the aortic position, as well as the condition of the heart chambers in short and long-term period (up to 10 years) after the implantation.
  3. To assess complications of the early and mid-term follow-up periods of aortic valve replacement using the "TiAra" prosthesis.

This study does not presuppose implementation of comparison groups.

Read the detailed description

Cardiovascular system diseases are one of the main causes of death worldwide. Heart valve diseases are considered one of the most important issues associated with the cardiovascular system. The replacement of heart valves includes the production of prostheses that provide functional consistency with exceptionally high reliability and appropriate fatigue strength. The proposed new biological valve with a frame made of super-elastic material allows preserves the natural biomechanics of the reconstructed valve and has high biocompatibility and resistance to infection due to the use of biological material as a frame covering. The "TiAra" bioprosthetic valve has the ability to deform during the cardiac cycle in accordance with the deformations of the fibrous structures of the patients' aortic root. The implanted valve fully integrates into the native aortic root.

The purpose of these clinical trials is to obtain clinical data confirming the efficacy and safety of the bioprosthesis under normal conditions in humans.

The expected clinical benefit involves the treatment of valvular disease with restoration of intracardiac hemodynamics during implantation of the "TiAra" bioprosthetic valve, followed by remodeling of the heart chambers, which should lead to an improvement in heart function and quality of life of the patient.

The expected risks are associated with taking anticoagulant therapy during the first three months after implantation, or as a result of prolonged anticoagulant therapy, in the presence of concomitant rhythm disturbances, and consist in the possibility of hemorrhagic or thromboembolic complications. In order to reduce the risks caused by anticoagulant therapy, it is planned to carry out measures aimed at restoring the sinus rhythm and ensuring proper control of the indicators of the blood coagulation system.

02

Conditions studied

  • Aortic Valve Disease
  • Artificial Heart Valves

Keywords

  • aortic valve
  • aortic valve bioprothesis TiAra
  • valve bioprosthesis
  • hemolysis
  • hemolytic anemia
  • a heart stroke
  • myocardial infarction
  • hemorrhaging and bleeding
  • heart arrhythmia
  • nonstructural dysfunction
  • pannus
  • prosthesis-patient mismatch
  • dislocation
  • paraprosthetic and transprosthetic regurgitation
  • heart failure
  • breast-pang
  • structural deterioration
  • valve thrombosis
  • thromboembolism
  • encarditis
  • a reoperation
03

In context

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.

Browse Aortic Valve Disease studies →

Lead sponsor

Closed Joint-Stock Company NeoCor is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

As part of these clinical trials (studies), the use of comparison groups is not planned.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient's written consent to participate in the study and the absence of restrictions on physical movement (diseases of the musculoskeletal system and diseases of the central nervous system, accompanied by cognitive disorders (disorientation, inability to independently reach the destination).
  2. The patient is a resident of the city* (suburb) where the institution is conducting study.

    * - participation is also possible for those living in the rural areas, but they have to be able to make visits to the Research Center.

  3. Age: 60-70 years old with a of 3 years or more. Or a person younger than 60 with to taking anticoagulants, or with increased risk of their use, consciously choosing a biological prosthesis for valve replacement.
  4. Isolated aortic valve disease.
  5. Real intervention on the heart valve is primary.
  6. Absence of concomitant interventions on the heart and thoracic aorta**.

    ** - Coronary artery bypass grafting, correction of tricuspid valve disease, previously treated congenital heart defects, aortic intervention

  7. The intervention on the valve is planned (that is, it is not carried out in expedited/urgent manner or is not a "rescue" operation).
  8. Absence of acute and subacute infective endocarditis.
  9. The following factors should not be present before surgery: high pulmonary hypertension (pulmonary arterial systolic pressure more than 60 mmHg), functional class 4 (according to the Functional Classification) while in ongoing treatment, less than 30%.

Exclusion criteria

Exclusion Criteria:

  1. The presence of severe somatic, neurological, mental diseases and infectious diseases that worsen the prognosis of long-term survival (ischemic heart disease, tuberculosis, human immunodeficiency viruses, Alzheimer's disease, epilepsy, insulin-requiring diabetes, kidney disease with less than 85 mL/min, chronic lung disease requiring chronic and bronchodilators, multifocal atherosclerosis (intermittent claudication, carotid arteries stenosis of more than 50%, prior and planned interventions on abdominal area, carotid arteries or arteries of the lower extremities).
  2. The patient has any not related to the underlying cardiovascular system disease pathology that will lead to the death of the patient in less than 1 year.
  3. The patient is currently participating in a study of a new drug or other medical devices.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. 1. Incidence of Treatment-Emergent Adverse Events, requiring repeated surgical intervention in the long term (long-term safety and durability)

    Long-term safety of the "TiAra" epoxy-treated prosthesis made with xenopericardium will be evaluated by the frequency of complications associated with the valve. Device safety is defined as the absence of severe adverse events associated with the device or procedure, assessed by the following clinical phenomena: Death Severe complications of the heart Life-threatening bleeding Any bioprosthesis-related dysfunction, migration, thrombosis or other complication requiring an open-heart surgery or repeated intervention. Myocardial infarction or progression of a chronic form of ischemia requiring percutaneous coronary intervention and coronary artery bypass grafting Access site complications Stroke

    Time frame: Up to 12 years from the moment of implantation .

  2. 2. Incidence of Treatment-Emergent Adverse Events, requiring repeated surgical intervention in the short term (short-term safety)

    Short-term safety of the "TiAra" epoxy-treated prosthesis made with xenopericardium in the treatment of isolated mitral and aortic valve diseases will be evaluated by the frequency of complications associated with the valve. Device safety is defined as the absence of severe adverse events associated with the device or procedure, assessed by the following clinical phenomena: hemolysis hemolytic anemia a heart stroke myocardial infarction hemorrhaging and bleeding heart arrhythmia nonstructural dysfunction pannus prosthesis-patient mismatch dislocation paraprosthetic and transprosthetic regurgitation heart failure breast-pang structural deterioration valve thrombosis thromboembolism encarditis a reoperation

    Time frame: Up to 12 years from the moment of implantation

07

Study locations

1 of 1 sites recruiting
  • Research Institute for Complex Problems of Cardiovascular Diseases, Russia
    Kemerovo, Kemerovo Region 650002, Russian Federation
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Aug 2025, 50 months after the start.

Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 50 months is close to that.

Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 21, 2023
StartActual
Jun 1, 2021
Primary completionEst.
Aug 10, 2025
CompletionEst.
Aug 10, 2026
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05998694
Lead sponsor
Closed Joint-Stock Company NeoCor
Collaborators
CT Medical Limited Liability Company, Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jun 1, 2021
Primary completion
Aug 10, 2025 (estimated)
Completion
Aug 10, 2026 (estimated)
Last update
Sep 25, 2024

Study contacts

Alexey Evtushenko, MD,PhD
Contact
ave@kemcardio.ru
+7 (3842) 64-33-08
Denis Lebedev, MD
Contact
mdlebedevd@mail.ru
+79138456592
Alexey Evtushenko, MD,PhD
principal investigator · Research Institute for Complex Problems of Cardiovascular Diseases, Russia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion